Supreme Court of Canada denies Eli Lilly leave to appeal
in olanzapine section 8 damages action. On November 8,
2018, Eli Lilly was denied leave to appeal (docket No. 38077) the Federal Court of Appeal (FCA)'s
decision (reported here) which affirmed the trial
decision awarding more than $70 million to Teva under section 8 of
the Patented Medicines (Notice of Compliance) Regulations
in respect of olanzapine (Eli Lilly's
ZYPREXA). The FCA granted Teva's cross-appeal
seeking to add to its recovery lost pipefill sales and an
adjustment to account for an under-reporting of sales in the data
relied on by both parties' experts.
Supreme Court of Canada denies Teva leave to appeal in
levofloxacin damages assessment. On November 8, 2018, Teva
was denied leave to appeal (docket No. 38033) the FCA's decision (reported here) which affirmed the trial
judge's quantification of damages (close to $19 million) from
infringement of Janssen's patent for
levofloxacin (LEVAQUIN). The